PRECISION BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.9 USD | +0.62% |
|
+1.26% | +17.81% |
Financials (USD)
| Sales 2024 * | 29.73M | Sales 2025 * | 18.47M | Capitalization | 89.34M |
|---|---|---|---|---|---|
| Net income 2024 * | -30M | Net income 2025 * | -64M | EV / Sales 2024 * | 0.04 x |
| Net cash position 2024 * | 88.17M | Net cash position 2025 * | 64.24M | EV / Sales 2025 * | 1.36 x |
| P/E ratio 2024 * |
-2.94
x | P/E ratio 2025 * |
-2.26
x | Employees | 109 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Precision BioSciences, Inc.
More recommendations
More press releases
| 1 day | +0.62% | ||
| 1 week | +1.26% | ||
| 1 month | +23.09% | ||
| 3 months | +1.42% | ||
| 6 months | +17.81% | ||
| Current year | +17.81% |
1 week
11.69
13.32
1 month
10.1313.44
Current year
9.1519.43
1 year
8.2525.20
3 years
8.25431.40
5 years
8.25710.11
10 years
8.25710.11
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Amoroso
CEO | Chief Executive Officer | 46 | 21-10-14 |
Jeff Smith
FOU | Founder | - | 06-01-25 |
John Kelly
DFI | Director of Finance/CFO | 57 | 20-10-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kevin Buehler
CHM | Chairman | 66 | 19-11-07 |
Geno Germano
BRD | Director/Board Member | 63 | 20-03-09 |
Samuel Wadsworth
BRD | Director/Board Member | 75 | 21-11-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.16% | 2 M€ | -25.75% | ||
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 12.9 | +0.62% | 22,967 |
| 24-05-30 | 12.82 | +4.48% | 87,651 |
| 24-05-29 | 12.27 | -3.00% | 32,267 |
| 24-05-28 | 12.65 | -0.71% | 22,165 |
| 24-05-24 | 12.74 | -2.00% | 18,649 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Companyâs in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).
Calendar
2024-06-04
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
12.9
USD
Average target price
33
USD
Spread / Average Target
+155.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.81% | 89.34M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- DTIL Stock
